ArticleCurrent medical imaging2025
Exploring the Prevalence and Coexistence of Metabolic Dysfunction-associated Steatotic Liver Disease in Type 2 Diabetes Mellitus Patients Using Ultrasound: A Cross-sectional Study
Article in Current medical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A prospective study on the role of non-invasive tests in the evaluation of diabetes mellitus associated steatotic liver disease.Scientific reports · 2025Article
- Diagnosis and Monitoring of Metabolic Dysfunction Associated with Fatty Liver Disease in Primary Care Patients with Risk Factors-EsteatoGal Study.Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundType 2 diabetes Mellitus (T2DM) increases vulnerability to metabolic dysfunction-associated steatotic liver disease (MASLD). Therefore, this study aims to determine the prevalence and coexistence of MASLD in patients with T2DM using ultrasound.
methodsThis cross-sectional retrospective study included 168 patients with T2DM from multiple diabetes clinics in Abha City, Asir region, recruited between August 2023 and December 2023. Adult patients aged 18 and over with T2DM were included, and data was extracted from patient files. All patients were examined by ultrasound to determine the prevalence and coexistence of MASLD in patients with T2DM. Hepatic steatosis on Bmode ultrasound is qualitatively classified on a four-point scale: normal (0), mild (1), moderate (2), and severe (3).
resultsOut of 168 patients, 68.4% were identified with MASLD, mostly with diffuse liver (97.4%) diagnosed through ultrasound. MASLD was significantly higher in individuals with uncontrolled diabetes (72.5%) than those with controlled diabetes (46.2%), with a significant difference (p=0.015) and an odds ratio (OR) of 3.081, indicating uncontrolled diabetics are over three times more likely to develop MASLD. The uncontrolled group had a statistically significant larger liver size than the control group (13.6cm ±1.43 vs. 13.0cm ±1.20, respectively: [p=0.032, 95%CI 0.053-1.12]). Furthermore, a notable association was observed between increased BMI and the prevalence of MASLD in individuals with T2DM. Furthermore, no significant association was found between the duration of diabetes and the severity of MASLD, nor between the grading of MASLD and gender.
conclusionThis study highlights a crucial association between uncontrolled diabetes and increased MASLD prevalence, emphasizing the importance of diabetes management in reducing MASLD risk.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.